Вы здесь


R&D Our new company’s mission-defined direction is the development of innovative drugs and their introduction into production.

We are actively involved in research under the federal target program "Development of the Pharmaceutical and Medical Industry of the Russian Federation until 2020 and beyond"

Pharmasyntez has 5 patents of the Russian Federation. Our staff have published over 20 scientific papers.     

Completed Phase II / III clinical trials of the new anti-TB drug thioureidoiminomethylpyridine perchlorate (Perhlozone®) tablets 400 mg:


  • Studies completed in June 2012         
  • Laboratory scale process for API of thioureidoiminomethylpyridine perchlorate completed.         
  • Obtained permission to conduct Phase I clinical trials of thioureidoiminomethylpyridine perchlorate-based drug in capsules.         
  • Studies initiated in the cities of Yaroslavl and Smolensk.


Screening studies of other biologically active chemical compounds including Mycobacterium tuberculosis active agents (thiosemicarbazone derivatives) in process

as well as comparative preclinical and clinical studies of Pharmasyntez products.

We are proud to cooperate with leading institutes and universities in Russia:

  • SB RAS A.E. Favorskiy Irkutsk Research Institute of Chemistry – Director Academic Boris Trofimov     
  • ESSC SB RAMS Reconstructive and Plastic Surgery – Director Eugeny Grigoriev, RAMS Associate Member     
  • SB RAS Siberian Institute of Plant Physiology and Biochemistry – Director Prof. Viktor Voinikov     
  • Cooperation agreement to be signed with Institution of the Russian Academy of Sciences I.Y.
  • Postovsky Institute of Organic Synthesis Ural Branch of RAS - Academic Valery Charushin    
  • Irkutsk State Medical Academy of Postgraduate Education - President Prof. Vladimir Shprakh     
  • Angarsk State Technical Academy of the Ministry of Education and Science, Institute of Biophysics (Angarsk) – President Prof. A. Badennikov     
  • State Budget Institution of Higher Education State Medical University of Ministry of Health and Social Development of the Russian Federation – President Prof. Igor Malov     
  • Federal State Budget Institution St. Petersburg Research Institute of Phthisiopulmonology of the Ministry of Health and Social Development of the Russian Federation – Director Prof. Petr Yablonsky, MD     
  • FSBI Ural Research Institute of Phthisiopulmonology - Director Prof. Sergey Skornyakov     
  • FSBI Novosibirsk Research Institute of Tuberculosis - Director Prof. Vladimir Krasnov     
  • Scientific and Production Company (SPC) Nanosystems (Moscow) - Director Andrey Molodanov

We also appreciate cooperation with our foreign partners:

  • Dong-A Pharmaceutical Co., Ltd. Seoul,Korea
  • Nuron Biotech, USA